Market Overview

J.P. Morgan Reiterates Overweight Rating on Pfizer

Share:
Related PFE
JPMorgan: Monsanto Shares Could Hit $180 Over The Next 5 Years
Pfizer Updates CHAMPIX To Add New Safety And Efficacy Data In European Union
Gain 50% From This Bidding War, Part II (Seeking Alpha)

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Pfizer (NYSE: PFE).

J.P. Morgan noted, “Maintain Overweight rating. We see Pfizer offering an attractive mix of 1) inexpensive valuation (11x '13 EPS), 2) an approaching nearterm new product cycle with 3) a high FCF/dividend yield, and 4) limited earnings risk, in our view. We see Pfizer's business unit divestitures as potentially unlocking significant value and anticipate continued high levels of capital return to shareholders, including what we forecast will be $10+ billion of share repurchase in 2013.”

Pfizer closed on Friday at $24.89.

Latest Ratings for PFE

DateFirmActionFromTo
May 2016BerenbergInitiates Coverage onHold
May 2016Credit SuisseMaintainsOutperform
May 2016Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!